Welcome to our dedicated page for Shoulder Innovations news (Ticker: SI), a resource for investors and traders seeking the latest updates and insights on Shoulder Innovations stock.
Shoulder Innovations develops and commercializes medical technology for the shoulder surgical care market, with implant systems for total and reverse shoulder arthroplasty and related tools for preoperative planning and procedural efficiency. Its ecosystem includes InSet shoulder arthroplasty systems, the ProVoyance planning platform, instrument systems, specialized support and surgeon collaboration.
Company news commonly covers product launches and FDA 510(k) clearances, including additions to the I-Series portfolio, quarterly and annual financial results, enabling-technology partnerships, board and committee changes, and management presentations at medical technology and musculoskeletal conferences.
Shoulder Innovations (NYSE: SI) said members of management will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3, 2025 at 8:30 a.m. ET / 5:30 a.m. PT. The event is scheduled as a live session with an archived webcast available after the presentation.
Investors can access the live and archived presentation on the company’s InvestorRelations website at https://ir.shoulderinnovations.com/.
Shoulder Innovations (NYSE: SI) announced the full commercial launch of the InSet™ 70 humeral stem on Sept. 22, 2025 in Grand Rapids, Mich.
The InSet™ 70 expands the company’s I-Series humeral stem line (which began with the InSet™ 95 in 2024), is cleared for both anatomic and reverse shoulder arthroplasty, and addresses indications including osteoarthritis, avascular necrosis, rheumatoid and traumatic arthritis, irreparable cuff tears, and certain revision cases.
Company statements highlight the InSet™ 70’s bone-sparing design, initial fixation comparable to the longer InSet™ 95, simplified surgical workflow, and claimed optimized biomechanics intended to support improved shoulder function for patients.
Shoulder Innovations (NYSE: SI) reported third-quarter 2025 results on Nov 11, 2025, with Q3 revenue of $11.8M, up 58% year-over-year, and 1,584 implant systems sold (up 53%). Gross margin was 76.2%. SG&A rose 78% to $15.1M and R&D rose 40% to $1.5M, producing an operating loss of $7.6M and net loss of $8.7M. Adjusted EBITDA loss was $7.5M. Cash and marketable securities totaled $137M, reflecting ~$115M of IPO and convertible note proceeds. The company raised full‑year 2025 revenue guidance to $45–46M (growth ~42–45% vs 2024).
Shoulder Innovations (NYSE: SI) announced that CEO Rob Ball will present at the Jefferies Global Healthcare Conference on Tuesday, November 18, 2025.
Presentation time: 8:30 a.m. GMT / 3:30 a.m. EST. A live and archived version of the fireside chat will be available on the company’s Investor Relations website at https://ir.shoulderinnovations.com/.
Shoulder Innovations (NYSE: SI) will release third quarter 2025 financial results after market close on November 11, 2025. Management will host a conference call at 4:30 p.m. ET / 1:30 p.m. PT the same day to discuss results.
Investors can join by phone using domestic dial-in (877) 407-8216, international dial-in (412) 902-1015 and access code 13756311. A live and archived webcast will be available in the Investor Relations section at https://ir.shoulderinnovations.com/.
Shoulder Innovations (NYSE:SI) has announced the full commercial launch of its InSet™ 70 Humeral Stem across the United States, expanding its I-Series humeral stem product line. The new implant, complementing the InSet™ 95 launched in 2024, is designed for both anatomic and reverse shoulder arthroplasty procedures.
The InSet™ 70 is indicated for various clinical applications, including non-inflammatory degenerative joint disease, rheumatoid and traumatic arthritis, and functional deformity correction. For reverse procedures, it's also indicated for irreparable cuff tears with or without arthritis and device revisions with sufficient bone stock. The device offers bone-sparing utility while maintaining excellent initial fixation and simple workflow.
Shoulder Innovations (NYSE:SI) reported strong Q2 2025 financial results with net revenue increasing 33% year-over-year to $11.0 million. The company sold 1,503 total implant systems, up 34% from the previous year, while maintaining a robust gross margin of 76.2%.
The quarter was marked by significant financial developments, including a $40 million convertible notes financing and completion of an IPO raising $75 million in gross proceeds. The company's surgeon customer base expanded by nearly 50% year-over-year. For full-year 2025, Shoulder Innovations projects revenue between $42-44 million, representing 33-39% growth.
However, the company reported an increased net loss of $19.2 million, primarily due to a $13.1 million expense related to changes in warrant liability and Series E purchase option valuations.
Shoulder Innovations (NYSE:SI), a commercial-stage medical technology company focused on the shoulder surgical care market, has scheduled two important events for September 9, 2025. The company will release its Q2 2025 financial results before the market opens. Additionally, management will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference at 8:30 a.m. ET.
Investors can access the live and archived fireside chat through the company's investor relations website.
Silvergate Capital Corporation (NYSE:SI) announced on March 17, 2023, that it received a letter from the NYSE regarding non-compliance with listing standards due to the late filing of its Annual Report on Form 10-K for the year ended December 31, 2022. The Company is working to complete the necessary information but requires more time. The NYSE may monitor the situation for up to six months, with potential suspension or delisting if compliance is not achieved. Currently, this does not affect the trading of Silvergate's securities aside from an 'LF' indicator being added to its trading symbols.
Silvergate Capital Corporation (NYSE:SI) announced its plan to wind down operations and voluntarily liquidate Silvergate Bank, aiming for an orderly process in accordance with regulatory requirements. The decision follows recent industry challenges, and the company asserts this is the best course to ensure the full repayment of all deposits. Silvergate is also evaluating how to resolve claims and maintain the value of its assets, including proprietary technology and tax assets. The Silvergate Exchange Network (SEN) will be discontinued, though other deposit services will remain operational.